Brisbane based medical device company, Oventus Medical will launch their new Victorian 3D printing facility at CSIRO today.
The additive manufacturing plant that uses titanium 3D printing technology to produce the customised O2Vent sleep apnoea device, is located at CSIRO’s Clayton site adjacent to their Lab 22 additive manufacturing centre.
The state-of-the-art facility is the next step in Oventus’ successful collaboration with CSIRO that has seen an initial R&D project develop into an ongoing beneficial partnership.
This valuable collaboration between Australian researchers and industry is paving the way for innovation in 3D design and production processes, as well as the treatment of obstructive sleep apnoea.
Research Director of CSIRO Manufacturing, Dr Keith McLean attributes the science organisation’s unique multidisciplinary capabilities for the speedy delivery of the Oventus project.
“Combining our research team’s additive manufacturing experience with the software capabilities of CSIRO’s Data61, meant we could create a one stop in-house process for making personalised mouth pieces that are individualised for each Oventus customer,” Dr McLean said.
“Additionally, we have been able to help Oventus upscale their manufacturing process to allow large volume manufacturing of the devices at the Clayton facility.”
Oventus founder, Dr Chris Hart, agrees that his business has enjoyed a productive partnership with the research body, taking advantage of CSIRO’s cutting edge capability in both the additive manufacturing and computational modelling space.
“CSIRO were able to help us not only develop the 3D printing process, but also create the crucial software needed to design the individual devices,” Dr Hart said.
“Because a patient’s bite is as individual as his fingerprint, we needed special software to help us create a perfectly customised O2Vent from a patient’s dental imprints.”
The O2Vent works by delivering air to the back of the mouth, alleviating multiple sites of obstruction including the nose, soft palate and tongue.
Oventus recently listed on the ASX following a successful IPO raising $12 million and is well on track to drive meaningful revenue growth in FY17 and beyond.
Oventus is set to launch onto the US market in early 2017, where over 37 million people regularly suffer from snoring.